Lerato Mohapi to Anti-Retroviral Agents
This is a "connection" page, showing publications Lerato Mohapi has written about Anti-Retroviral Agents.
Connection Strength
0,460
-
Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa. J Acquir Immune Defic Syndr. 2013 Mar 01; 62(3):322-328.
Score: 0,077
-
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91.
Score: 0,070
-
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010 Oct 14; 363(16):1499-509.
Score: 0,065
-
Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS. 2010 Sep 10; 24(14):2263-70.
Score: 0,065
-
Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration. S Afr Med J. 2009 Sep; 99(9):653-60.
Score: 0,060
-
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing. Antimicrob Agents Chemother. 2022 09 20; 66(9):e0238521.
Score: 0,037
-
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. J Int AIDS Soc. 2022 06; 25(6):e25905.
Score: 0,036
-
Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV. Front Immunol. 2021; 12:676980.
Score: 0,034
-
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010 Mar 15; 201(6):803-13.
Score: 0,016